Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.27    
    

	 	 	

 

40 Bear Hill Road

Waltham, MA 02451

Tel: (781) 890-1199

Fax: (781) 890-9335

www.beyondgenomics.com

AGREEMENT FOR MEMBERS OF RESEARCH AND DEVELOPMENT

ADVISORY BOARD (RDAB) 

        THIS
AGREEMENT is made and entered into as of April 1, 2004 by and between Jan van der Greef, PhD, an individual ("Advisor"), whose address is set forth on the last page of this
document, and Beyond Genomics, Inc., a company organized under the laws of the State of Delaware (the "Company"). 

        The
Company and Advisor agree as follows: 

        Section 1. Services.    The Company hereby engages Advisor to provide, and Advisor agrees to provide, under the terms and
conditions of this Agreement, the services described on Exhibit A attached hereto and incorporated by this reference (hereinafter the
"Services"). If an Inventions Agreement is signed by the Company and Advisor and attached as an Exhibit B to this Agreement, it will become a
part of this Agreement and will be governed by the general terms and conditions hereof. 

        Section 2. Expenses.    The Company shall reimburse Advisor for reasonable and necessary
out-of-pocket expenses incurred by Advisor in the performance of the Services, provided such out-of-pocket expenses are approved in advance by the
Company, and are supported by reasonable documentation. 

        Section 3. Consultant to the Company.    Advisor is not, nor shall Advisor be deemed to be at any time during the term of
this Agreement, an employee of the Company. Advisor's status and relationship with the Company shall be that of consultant. Advisor shall not state or imply, directly or indirectly, that Advisor is
empowered to bind the Company without the Company's prior written consent. Nothing herein shall create, expressly or by implication, a partnership, joint venture or other association between the
parties. Advisor will be solely responsible for payment of all charges and taxes arising from his or her relationship to the Company as an Advisor. 

        Section 4. Cancellation of Services.    Either party may at any time terminate the performance of all or any portion of
the Services to be provided hereunder upon 60 days prior written notice to the other stating its intention to terminate and specifying that all or a portion of the Services will be terminated
and the date upon which such termination shall be effective. 

        Section 5. Term of Agreement; Termination.    The term of this Agreement and the Advisor's Services hereunder shall
commence as of the date of this Agreement and unless terminated earlier as a result of the death, physical incapacity or mental incompetence of the Advisor, which shall result in automatic
termination, or pursuant to Section 4 of this Agreement, it shall continue in effect until March 31, 2008 (the "Initial Term"). The term of this Agreement shall be extended beyond the
Initial Term for one or more additional one (1) year periods (individually, an "Additional Term"), unless either party desires not to extend the
term of this Agreement for an Additional Term, in which case such party shall give the other party at least thirty (30) days' prior written notice of the intention not to extend the Agreement
for an Additional Term. Except as otherwise explicitly provided herein, the provisions of 

CONFIDENTIAL

1

 

Sections
6 through 12 of this Agreement shall survive the termination or expiration of this Agreement for any reason. 

        Section 6. Warranties of Advisor.    Advisor represents to the Company that (i) with respect to any information,
know-how, knowledge or data disclosed by Advisor to the Company in the performance of this Agreement, Advisor has the full and unrestricted right to disclose the same; and
(ii) Advisor is free to undertake the Services required by this Agreement, and there is, and will be, no conflict of interest between Advisor's performance of this Agreement and any obligation
Advisor may have to other parties. 

        Section 7. Covenants of Advisor.    Advisor agrees that without the prior written consent of the Company, during the term
of this Agreement, Advisor shall not become employed by, advise, become associated with, or perform consulting services for any entity that is, or, as a result of such activities, would become, a
competitor in the Company's field of business or otherwise would create a conflict of interest for Advisor with Advisor's obligations to the Company. 

        Section 8. Confidentiality.    Advisor agrees to hold all Confidential Information (as hereinafter defined) of the
Company (or other parties whose Confidential Information the Company has in its possession under obligations of confidentiality) in trust and strict confidence and, except as may be authorized by the
Company in writing, shall not use for any purpose other than the performance of the Services under this Agreement, nor disclose such Confidential Information to any person, association, company,
entity or other organization (whether for profit or not for profit). 

        As
used herein, "Confidential Information" shall mean all knowledge and information which the Advisor has acquired or may acquire as a result of, or related to, his or her relationship
with the Company, including but not limited to, information concerning the business, finances, operations, strategic planning, research and development activities, products, improvements, processes,
trade secrets, services, cost and pricing policies, formulae, diagrams, schematics, notes, data, memoranda, methods, know-how, techniques, inventions, and marketing strategies of the
Company. Confidential Information shall also include information received by the Company from third parties under an obligation of confidentiality. Notwithstanding the foregoing sentence, such
Confidential Information does not include (i) information which is or becomes publicly available (except as may be disclosed by the Advisor in violation of this Agreement) or
(ii) information acquired by the Advisor from a third-party source other than the Company, which source legally acquired such information under no obligation of confidentiality. 

        Section 9. Company Data.    Any data or other materials furnished by the Company for use by Advisor in connection with
the Services shall remain the sole property of the Company and will be held in trust and confidence by Advisor in accordance with Section 8. 

        The
Company may obtain the return of any data or other materials furnished to Advisor upon written notice to Advisor requesting such return, and in any event Advisor shall promptly
return such data or materials upon termination of this Agreement. 

        Section 10. Miscellaneous.    This Agreement together with all exhibits hereto, contains the entire understanding of the
parties with respect to the matters contained herein, and supersedes all proposals and agreements, written or oral, and all other communications between the parties relating to the subject matter of
this Agreement. This Agreement shall be governed by and construed in accordance
with the laws of the Commonwealth of Massachusetts. This Agreement may not be modified or amended except in writing signed or executed by Advisor and the Company. In the event any provision of this
Agreement is held to be unenforceable or invalid because it is overbroad or too far reaching, such provision shall be deemed to be revised so that it applies to the maximum extent permitted by law. 

*        *        *        * 

(Remainder
of page intentionally left blank) 

CONFIDENTIAL

2

 

        IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date last below written. 

	

BEYOND GENOMICS, INC.	
 	

ADVISOR:
	

By:	
 	

/s/ Muzammil Mansuri
 Name: Muzammil Mansuri, Ph.D.

Title: Executive Chairman	
 	

/s/ Jan van der Greef
 Signature
	

 	
 	

 	
 	

/s/ Jan van der Greef
 Name (please print)
	

 	
 	

 	
 	

 Address
	

 	
 	

 	
 	

 City, Postal Code
	

 	
 	

 	
 	

 Country

CONFIDENTIAL

3

   EXHIBIT A

	Title	 	•	 	Member, R & D Advisory Committee ("RDAB")
	

Term	
 	

•	
 	

April 1, 2004–March 31, 2008
	 	 	•	 	Automatically renewable for additional 1 year term with agreement between both parties. 30 day notice required for intent not to renew
	 	 	•	 	Agreement may be terminated by Company with 60 day notice
	

Time Commitment	
 	

•	
 	

Commit at least 20% of time to BG activities during the term of this Agreement
	 	 	•	 	Attend all RDAB meetings (at least 3 per year) as requested
	

Major Responsibilities	
 	

•	
 	

Serve as an active member of the BG Research and Development Advisory Board (RDAB).
	 	 	•	 	Provide guidance and substantial input into the development of the BG Metabolomics component of the Systems Biology technology platform.
	 	 	•	 	Assist in enhancing the relationship between BG and TNO.
	 	 	•	 	Manage technology transfer as requested to BG.
	 	 	•	 	Assist in the identification and recruitment of key technologists — scientific and computational.
	 	 	•	 	Assist in the execution of additional proof of concept technology plans in the Metabolomics component of Systems Biology as requested by BG.
	 	 	•	 	Assist in the development of scientific relationships/collaborations/programs with prospective pharmaceutical, biotech and academic customers for projects, as requested by BG.
	 	 	•	 	Jointly develop intellectual property for the exclusive benefit of BG in the field of Systems Biology.
	 	 	•	 	Assist with the promotion of Beyond Genomics through publications, lectures, etc. as requested by BG.
	

Cash Compensation	
 	

•	
 	

$70,000 USD Annually (payable on a monthly basis)
	 	 	•	 	$30,000 USD One-time bonus payable upon the closing of the Company's next institutional financing round greater than $5M USD
	 	 	•	 	Plus reasonable Company related out-of-pocket expenses
	

Equity	
 	

•	
 	

150,000 non-qualified stock options (four year quarterly vesting)

CONFIDENTIAL

4

   EXHIBIT B

INVENTIONS AGREEMENT 

	1.
	If
at any time or times during the term of my Agreement for Members of the Research and Development Advisory Board (the "RDAB Agreement") with Beyond Genomics, Inc. (the
"Company"), I ("Advisor") shall (either alone or with others) make, conceive, create, discover, invent or reduce to practice any idea, invention, modification, discovery, design (whether the design is
ornamental or otherwise), development, improvement, process, molecule, organism, software program, work of authorship, documentation, formula, data, technique, know-how, trade secret or
other intellectual property whatsoever or any interest therein (whether or not patentable or registrable under copyright, trademark or similar statutes, or subject to analogous protection) (herein
called "Developments") that:

	(a)
	relates
to the actual business of the Company or a business that the Company has actively discussed entering, and is derived from information learned as a result of my service as a
member of the Research and Development Advisory Board; or

	(b)
	results
from projects or tasks assigned to me by the Company; or

	(c)
	results
from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company, 

then
such Developments and the benefits thereof shall immediately become the sole and absolute property of the Company and its assigns, as works made for hire or otherwise. I shall promptly disclose
to the Company (or any persons designated by it) each such Development. I hereby assign any rights, including but not limited to any copyrights and trademarks, I may have or acquire in the
Developments and benefits and/or rights resulting there from to the Company and its assigns without further compensation and shall communicate, without cost or delay, and without disclosing to others
the same, all available information relating thereto (with all necessary plans and models) to the Company. I
hereby waive, to the extent permitted by law, any moral rights I may have with respect to such Developments and neither the Company nor any of its customers or licensees will be required to attribute
my inventorship or authorship of any Developments incorporated in any of the Company's products. 

	2.
	Upon
disclosure of each Development to the Company, I will, during the term of my RDAB Agreement with the Company and at any time thereafter, at the request and cost of the Company,
sign, execute, make and do all such deeds, documents, acts and things as the Company and its duly authorized agents may reasonably require:

	(a)
	to
apply for, obtain and vest in the name of the Company alone (unless the Company otherwise directs) letters patent, copyrights, trademarks or other analogous protection in any
country throughout the world and when so obtained or vested to renew and restore the same; and

	(b)
	defend
any judicial, opposition or other proceedings in respect of such applications and any judicial, opposition or other proceedings or petitions or applications for revocation of
such letters patent, copyright, trademark or other analogous protection

	3.
	In
the event the Company is unable, after reasonable effort, to secure my signature on any letters patent, copyright, trademark or other analogous protection relating to a Development,
whether because of my physical or mental incapacity or for any other reason whatsoever, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent
and attorney-in-fact, to act for and in my behalf and stead to execute and file any such application or applications or other documents and to do all other lawfully permitted
acts to 

CONFIDENTIAL

5

 

further
the prosecution and issuance of letters patent, copyright or trademark registrations or other analogous protection thereon with the same legal force and effect as if executed by me. 

	4.
	I
acknowledge that the copyright and any other intellectual property right in designs, computer programs and related documentation, and works of authorship, created within the scope of
my RDAB Agreement with the Company, belong to the Company by operation of law.

	5.
	This
Agreement is a part of, and shall be governed by, the general terms and conditions of the RDAB Agreement dated as of today's date between the Company and me, which agreements
constitute my entire understanding with the Company relating to the subject matter hereof and supersede (to the extent enforceable) all previous oral or written communications, representation,
undertakings, or agreements by or with the Company. All capitalized terms used herein, unless otherwise defined, shall have the meanings assigned to them in the RDAB Agreement. 

*        *        *        *

(Remainder
of page intentionally left blank) 

CONFIDENTIAL

6

 

AGREED
TO this 1st day of April, 2004 by: 

	

BEYOND GENOMICS, INC.	
 	

ADVISOR:
	

By:	
 	

/s/ Muzammil Mansuri
 Name: Muzammil Mansuri, Ph.D.

Title: Executive Chairman	
 	

/s/ Jan van der Greef
 Signature
	

 	
 	

 	
 	

/s/ Jan van der Greef
 Name (please print)
	

 	
 	

 	
 	

 Address
	

 	
 	

 	
 	

 City, Postal Code

CONFIDENTIAL

7

QuickLinks

Exhibit 10.27Filed by Automated Filing Services Inc. (604) 609-0244 - Battle Mountain Gold Exploration Corp. - Exhibit 10.1

Execution Version 

FIRST AMENDMENT TO THE 
BRIDGE FINANCE FACILITY AGREEMENT

THIS FIRST AMENDMENT TO THE BRIDGE FINANCE FACILITY
AGREEMENT (this “Amendment”) is dated July 30, 2007 

BETWEEN: 

BATTLE MOUNTAIN GOLD EXPLORATION
CORP. AND 
BMGX (BARBADOS) CORPORATION as Borrowers 

OF THE FIRST PART 

AND: 

ROYAL GOLD, INC. 
as Bridge
Lender 

OF THE SECOND PART 

WHEREAS Borrowers and Bridge Lender are parties to that
  certain Bridge Finance Facility Agreement dated for reference March 28, 2007
  (the “Credit Facility”; capitalized terms used herein and not
  otherwise defined herein having the definitions provided therefor in the Credit
  Facility); 

WHEREAS Bridge Lender, Royal Battle Mountain, Inc., and
  Battle Mountain are parties to the Agreement and Plan of Merger, originally
  dated as of April 17, 2007, which is to be amended and restated simultaneously
  with this Amendment to the Credit Facility; and

WHEREAS Borrowers and Bridge Lender desire to enter into
this Amendment, which amends the Credit Facility by (i) extending the Final
Maturity Date from March 28, 2008 to June 6, 2008 and (ii) specifying the date
upon which the Bridge Lender must provide notice in the event it elects to
convert any or all amounts due to it under the Credit Facility into common stock
of Battle Mountain. 

NOW THEREFORE in consideration of the mutual covenants
and agreements herein set forth and other good and valuable consideration, the
receipt and sufficiency whereof is hereby acknowledged, the parties agree as
follows: 

2

1.       
AMENDMENTS TO CREDIT FACILITY. 

		(a) 	 The text of section 1.1(30)
        shall be deleted in its entirety and replaced by the following: 

	 	 	 	  

	 	 	(30) 	 “Final Maturity Date” means June
        6, 2008. 

	 	 	 	  

		(b) 	 The text of section 1.1(59)
        shall be deleted in its entirety and replaced by the following: 

	 	 	 	  

			(59) 	 “Merger Agreement” means the Amended
        and Restated Agreement and Plan of Merger dated of even date herewith,
        by and among Royal Gold, Royal Battle Mountain, Inc. and Battle Mountain.
      

	 	 	 	  

		(c) 	 The text of section 2.3 shall
        be deleted in its entirety and replaced by the following: 

	 	 	 	  

			 At any time during the term
        of this Credit Facility, the Bridge Lender shall have the right to convert
        all or any portion of the Obligations into shares of Battle Mountain common
        stock at a conversion price equal to $.60 per share; provided that, the
        Bridge Lender must provide written notice on or before April 4, 2008 of
        its election to convert pursuant to this section 2.3. 

2.       
REPRESENTATIONS AND WARRANTIES. To induce Bridge Lender to enter into
this Amendment, each of the Borrowers represents and warrants as follows,
acknowledges that the Bridge Lender is relying thereon in entering into this
Amendment, agrees that no investigation at any time made by or on behalf of the
Bridge Lender shall diminish in any respect whatsoever its right to rely
thereon, and agrees that all representations and warranties shall be valid and
effective as of the date when given or deemed to have been given and to such
extent shall survive the execution and delivery of this Amendment and the
provision of the Credit Facility: 

	 	(a) 	
      DUE AUTHORIZATION. The execution, delivery
      and performance of this Amendment has been duly authorized by all
      requisite corporate action on the part of Borrowers, this Amendment has
      been duly executed and delivered by Borrowers and this Amendment
      constitutes a valid and binding agreement of Borrowers, enforceable
      against Borrowers in accordance with its terms, except as the
      enforceability thereof may be limited by bankruptcy, insolvency or other
      similar laws relating to the enforcement of creditors’ rights generally
      and by general equitable principles.

	 	 	 
	 	(b) 	
      NO DEFAULT. Immediately before and after giving
      effect to this Amendment and the consummation of the transactions
      contemplated hereby, no Default or Event of Default is in
  existence.

3

	 	(c) 	
      BRING-DOWN. The warranties and representations of
      Borrowers contained in the Credit Facility and the Credit Facility
      Documents are true and correct in all material respects as of the date
      hereof, with the same effect as though made on such date, except to the
      extent that such warranties and representations expressly relate to an
      earlier date, in which case such representations and warranties were true
      and correct in all material respects as of such earlier
  date.

	3. 	 MISCELLANEOUS.
      

	  	  	  

		(a) 	 EXPENSES. Each party to this Amendment
        shall be liable for their own costs and expenses incurred in connection
        herewith. 

	  	  	  

	  	(b) 	 GOVERNING LAW. 

	  	  	  

			 (1) Governing Law. This Amendment shall
        be governed by and construed in accordance with the internal laws of the
        State of Nevada. 

	  	  	  

			 (2) Submission to Jurisdiction. Each party
        hereby irrevocably submits to the jurisdiction of the courts of State
        of Nevada and Colorado in any action or proceeding arising out of or relating
        to this Amendment and hereby irrevocably agrees that all claims in respect
        of any such action or proceeding may be heard and determined in such courts.
        Each party hereby irrevocably waives, to the fullest extent it may effectively
        do so, the defense of an inconvenient forum to the maintenance of such
        action or proceeding. Each party agrees that a final judgment in any such
        action or proceeding shall be conclusive and may be enforced in other
        jurisdictions by suit on the judgment or in any other manner provided
        by Law. 

	  	  	  

			 (3) Non-Exclusive. Nothing in this section
        3(b) shall affect the right of any party to serve legal process in any
        other manner permitted by Law or affect the right of a party to bring
        any action or proceeding against another party or its property in the
        courts of other jurisdictions. 

	  	  	  

			 (4) Trial by Jury. Each of the parties hereto,
        to the fullest extent permitted by Law, hereby waives its rights to a
        trial by jury. 

	  	  	  

		(c) 	 COUNTERPARTS. This Amendment may
        be executed in counterparts, each of which shall be deemed an original
        and all of which, taken together, shall constitute one and the same instrument,
        and may be delivered by a party by facsimile or similar means of recorded
        communication. 

4

	 	(d) 	
      SUCCESSORS AND ASSIGNS. This Amendment shall be
      binding upon and shall inure to the sole benefit of Borrowers and Bridge
      Lender and their respective successors and assigns in compliance with
      section 9.8 of the Credit Facility.

	 	 	 
	 	(e) 	
      SEVERABILITY. The provisions of this Amendment are
      intended to be severable. If any provision of this Amendment shall be held
      invalid or unenforceable in whole or in part in any jurisdiction, such
      provision shall, as to such jurisdiction, be ineffective to the extent of
      such invalidity or unenforceability without in any manner affecting the
      validity or enforceability thereof in any other jurisdiction or the
      remaining provisions hereof in any jurisdiction.

	 	 	 
	 	(f) 	
      FURTHER ASSURANCES. Each party to this Amendment
      shall do and perform or cause to be done and performed all such further
      acts and things and shall execute and deliver all such other agreements,
      certificates, instruments and documents as the other parties hereto may
      reasonably request in order to carry out the intent and accomplish the
      purposes of this Amendment and the consummation of the transactions
      contemplated hereby.

	 	 	 
	 	(g) 	
      CONTINUATION OF CREDIT FACILITY. Notwithstanding
      anything contained herein, the terms of this Amendment are not intended to
      and do not serve to effect a novation as to the Credit Facility. The
      parties hereto expressly do not intend to extinguish the Credit Facility.
      Instead, it is the express intention of the parties hereto to reaffirm the
      indebtedness created under the Credit Facility which is evidenced by the
      Note and secured by the Collateral. The Credit Facility as amended hereby
      and each of the Credit Facility Documents remain in full force and
      effect.

	 	 	 
	 	(h) 	
      CONSTRUCTION. Borrowers acknowledge that they have
      been represented by their own legal counsel in connection with the Credit
      Facility Documents and this Amendment, that they have exercised
      independent judgment with respect to the Credit Facility Documents and
      this Amendment, and that they have not relied on the Bridge Lender or its
      counsel for any advice with respect to the Credit Facility Documents or
      this Amendment.

	 	 	 
	 	(i) 	
      CREDIT FACILITY DOCUMENT. This Amendment shall
      constitute a Credit Facility Document.

(execution page follows)

IN WITNESS WHEREOF the parties have caused this
Amendment to be executed by their respective officers thereunto duly authorized,
as of the date first above written. 

BORROWERS: 

BATTLE MOUNTAIN GOLD EXPLORATION
CORP. 

By: /s/ Mark Kucher 
Name:
Mark Kucher 
Title:   Chairman, Chief Executive Officer and
President 

BMGX (BARBADOS) CORPORATION

By: /s/ Mark Kucher 
Name:
Mark Kucher 
Title:   Chairman, Chief Executive Officer and
President 

BRIDGE LENDER:

ROYAL GOLD, INC. 

By: /s/ Tony Jensen 
Name:
Tony Jensen 
Title:   President and Chief Executive Officer 

SIGNATURE PAGE TO FIRST AMENDMENT TO BRIDGE FINANCE FACILITY
AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]